• Explore /
  • Poster
  • / Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.

Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.

Abstract Video & Slides Poster

Authors

null

Gavin M. Marx

University of Sydney, Sydney, Australia

Gavin M. Marx , Amy Jo Chien , José A. García-Sáenz , Arlene Chan , Manuel Ruiz-Borrego , Carlos Hernando Barcenas , Michael P. Thirlwell , Maureen E. Trudeau , Ron Bose , Daniel Egle , Barbara Pistilli , Johanna Wassermann , Kerry A. Cheong , Dieter Semsek , Christian F. Singer , Daniel Hunt , Utpal Khambholja , Feng Xu , Naisargee Shah , Adam Brufsky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT02400476

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 536)

DOI

10.1200/JCO.2021.39.15_suppl.536

Abstract #

536

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Carlos Hernando Barcenas

Poster

2019 ASCO Annual Meeting

Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?

Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?

First Author: Naomi RM Schwartz

First Author: Bent Ejlertsen

First Author: Arlene Chan